resiquimod has been researched along with Cancer of Colon in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, MM; Chen, F; Chen, X; Faustman, DL; Jiang, M; Li, P; Liu, J; Oppenheim, JJ; Tross, D | 1 |
| Anz, D; Bourquin, C; Endres, S; Heidegger, S; Hotz, C; Noerenberg, D; Roetzer, LC; Sandholzer, N; Storch, B; Voelkl, A; Wurzenberger, C | 1 |
2 other study(ies) available for resiquimod and Cancer of Colon
| Article | Year |
|---|---|
A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
Topics: Adjuvants, Immunologic; Animals; Antibodies; Colonic Neoplasms; Female; Flow Cytometry; HMGN1 Protein; Imidazoles; Immunosuppression Therapy; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Receptors, Tumor Necrosis Factor, Type II; T-Lymphocytes, Regulatory | 2021 |
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Topics: Animals; Carcinoma; Cells, Cultured; Colonic Neoplasms; Cytokines; Dendritic Cells; Drug Screening Assays, Antitumor; Female; Imidazoles; Immune Tolerance; Interferon-alpha; Interleukin-1 Receptor-Associated Kinases; Interleukin-12; Interleukin-6; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Toll-Like Receptor 7; Tumor Escape | 2011 |